Form 4 holding
Director
QSAM Biosciences, Inc.
- Security class
- Common Stock
- Shares / value
- 2,883,943
- Estimated value
- $8,651,829
- Report date
- 06 Dec 2021
- Price
- $3.00
- Ownership
- Direct
David Charles Link
Insider Reports History
- Reporting-owner location
- Sioux Falls, SD
- Latest reporting-owner signature
-
/s/ David Charles Link
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for David Charles Link
Form 4 holding
Director
QSAM Biosciences, Inc.
- Security class
- Options to buy common
- Shares / value
- 55,000
- Estimated value
- Report date
- 24 Aug 2021
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
SAB Biotherapeutics, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 9,305
- Estimated value
- Report date
- 15 Jul 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
QSAM Biosciences, Inc.
- Security class
- Series E-1 Preferred Shares
- Shares / value
- 0
- Estimated value
- Report date
- 15 Feb 2021
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
QSAM Biosciences, Inc.
- Security class
- Series E-1 Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 06 Dec 2021
- Price
- Ownership
- Direct
Insider Reports Filed by David Charles Link
4
SABS
SAB Biotherapeutics, Inc.
- Report period
- 15 Jul 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 17 Jul 2024, 16:30
- Role
- Director
- Next action
- Open filing details
4
SABS
SAB Biotherapeutics, Inc.
- Report period
- 07 Dec 2022
- Transactions
- 2
- Transaction value
- +$49,999
- Accepted by SEC
- 09 Dec 2022, 08:01
- Role
- Director
- Next action
- Open filing details
5
QSAM Biosciences, Inc.
- Report period
- 31 Dec 2021
- Transactions
- 4
- Transaction value
- $0
- Accepted by SEC
- 15 Feb 2022, 05:11
- Role
- Director
- Next action
- Open filing details
4
SABS
SAB Biotherapeutics, Inc.
- Report period
- 22 Oct 2021
- Transactions
- 7
- Transaction value
- $0
- Accepted by SEC
- 26 Oct 2021, 21:49
- Role
- Director
- Next action
- Open filing details
3
SABS
Big Cypress Acquisition Corp.
- Report period
- 22 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 22 Oct 2021, 21:24
- Role
- Director
- Next action
- Open filing details